Amongst stage 0–3 breast cancer survivors, adherence to long-term adjuvant endocrine therapy (i.e., Tamoxifen and aromatase inhibitors) is associated with a significant increase in recurrence-free survival. The gene discussed is CYP19A1; the disease is breast cancer.